Forum Agenda

July 22, 13:30-17:30

Global Innovation of Antibodies and ADCs session

Stay tuned

13:30-13:45 Global Innovation Strategy of DualityBio
John Zhu: Chairman, DualityBio

 

13:45-14:00 Global Collaboration Opportunities and Clinical Progress of Alphamab Oncology's Product Pipeline
Ting Xu: Chairman & President, Alphamab Oncology

 

14:00-14:15 Restructuring the Value Chain of Antibody and ADCs from Local to Global
Cuiling Song: Senior Application & Product Director, Bailinke

 

14:15-14:30 Differentiated Clinical Strategies for ADC Global Expansion and Development
Tongtong Xue: CEO, MediLink Therapeutics

 

14:30-14:45 Global Collaboration Opportunities and Clinical Progress of ImmuneOnco's Product Pipeline
Wenzhi Tian: Founder & Chairman, ImmuneOnco Biopharmaceuticals

 

14:45-15:00 Beyond Supply: Innovative Toolchains to Systematically Accelerate ADC Development
Xiaojing An: Dean of Sino Biological Innovation Research Institute

 

15:00-15:15 Innovation Strategy of Lepu Biopharma
Ziye Sui: CEO, Lepu Biopharma

 

15:15-15:30 Innovation Strategy of 3S Bio
Yanli Liu: General Manager, 3S Bio

 

15:30-15:45 Antibody Innovation Strategy of Affinity Biopharma
Chen Liu: Founder, President & Co-CMO, Affinity Biopharma

 

15:45-16:00 Engineering Strategies to Maximize the Efficacy of Antibody-Drug Conjugates
Changshou Gao: CTO, Shanghai Allist Pharmaceuticals

 

16:00-16:15 Innovation Strategy of Mabwell
Ke Hu: Senior Vice President, Mabwell

 

16:15-16:30 Precision Modeling Empowers a New Paradigm in Drug R&D: Application Value of Fully Humanized Mouse Models in Preclinical Research
Yuan Dong: R&D Director, China, Genovo Biotech

 

16:30-16:45 A Global Perspective on ADC Development
Junli Zhang: Senior Vice President, ADC BU Head and MFG Sites Head, Zencore Biologics

 

16:45-17:00 AI-Driven Precision and Scalability Empowering Next-Generation Dual-Payload ADCs
Yi Yang: CSO, Biocytogen

 

17:00-17:15 Global Development Strategy of Transcenta Holding's Antibody Drugs
Xueming Qian: CEO, Transcenta Holding

 

17:15-17:30 Digital-Intelligence Integration: Reconstructing Cell Culture Media and Bioprocess Development
Max Wang: CEO, MediumBank